REGENXBIO (NASDAQ:RGNX) Announces Earnings Results

REGENXBIO (NASDAQ:RGNX) released its quarterly earnings data on Thursday. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.35, FiscalAI reports. REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%.The firm had revenue of $108.02 million for the quarter, compared to analyst estimates of $97.63 million.

Here are the key takeaways from REGENXBIO’s conference call:

• REGENXBIO ended the quarter with more than $310 million pro forma, following a $100 million AbbVie milestone and a $108 million follow-on offering. Management expects this to fund operations into Q4 2027, including the anticipated RGX-202 PDUFA date.
• RGX-202 enrollment and dosing in the confirmatory Duchenne muscular dystrophy study were completed ahead of schedule, with more than 60 patients across pivotal and confirmatory studies. The company plans to submit the first BLA module in Q3 2026 and initiate the global AFFINITY RISE trial in the first half of 2027.
• The FDA agreed that RGX-121’s existing data are sufficient for accelerated-approval review and said no additional studies, including a randomized controlled trial, are required for BLA resubmission. REGENXBIO plans to resubmit the application in Q3 2026 with longer-term efficacy, safety, imaging, and neurocognitive data.
• REGENXBIO and AbbVie began the Phase IIb/III NAAVIGATE study of sura-vec in diabetic retinopathy, triggering the $100 million milestone payment. The partners expect fourth-quarter top-line results from the ATMOSPHERE and ASCENT wet AMD studies, while longer-term follow-up showed durable effects and favorable safety through five years in wet AMD and 2.5 years in diabetic retinopathy.
• The company acknowledged that its U.S. patent covering Zolgensma has expired, although royalties will continue in roughly 20 countries outside the United States. Management highlighted Evrysdi coverage and potential future royalties from Itvisma as offsets, but did not provide specific royalty-rate guidance.

REGENXBIO Price Performance

RGNX traded up $0.78 during trading on Thursday, hitting $11.28. 1,766,472 shares of the stock traded hands, compared to its average volume of 1,848,277. REGENXBIO has a twelve month low of $5.45 and a twelve month high of $16.19. The company has a market cap of $583.18 million, a price-to-earnings ratio of -2.01 and a beta of 0.94. The business has a 50 day moving average price of $9.94 and a 200 day moving average price of $9.42.

Insider Buying and Selling at REGENXBIO

In other REGENXBIO news, insider Steve Pakola sold 2,161 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $13.64, for a total value of $29,476.04. Following the sale, the insider owned 213,009 shares of the company’s stock, valued at approximately $2,905,442.76. This trade represents a 1.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 73,803 shares of company stock valued at $886,937. Company insiders own 14.22% of the company’s stock.

Institutional Trading of REGENXBIO

Several institutional investors and hedge funds have recently modified their holdings of the business. Aquatic Capital Management LLC acquired a new stake in REGENXBIO in the third quarter valued at about $37,000. Captrust Financial Advisors acquired a new position in REGENXBIO during the second quarter worth about $85,000. Balyasny Asset Management L.P. acquired a new position in REGENXBIO during the fourth quarter worth about $150,000. Prudential Financial Inc. bought a new position in shares of REGENXBIO in the second quarter worth about $87,000. Finally, CANADA LIFE ASSURANCE Co lifted its holdings in shares of REGENXBIO by 271.8% in the second quarter. CANADA LIFE ASSURANCE Co now owns 10,839 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 7,924 shares during the last quarter. 88.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on RGNX shares. Morgan Stanley set a $16.00 target price on REGENXBIO in a research note on Friday, May 15th. Leerink Partners raised their price target on REGENXBIO from $17.00 to $18.00 and gave the company an “outperform” rating in a report on Monday, June 22nd. Bank of America reduced their price objective on shares of REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of REGENXBIO in a research report on Monday, June 8th. Finally, Robert W. Baird raised their target price on shares of REGENXBIO from $27.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.82.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.